AustralianSuper Pty Ltd Sells 82,261 Shares of United Therapeutics Corporation $UTHR

AustralianSuper Pty Ltd lowered its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 83.9% during the 4th quarter, Holdings Channel reports. The institutional investor owned 15,739 shares of the biotechnology company’s stock after selling 82,261 shares during the quarter. AustralianSuper Pty Ltd’s holdings in United Therapeutics were worth $7,669,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in UTHR. Darwin Global Management Ltd. purchased a new position in United Therapeutics during the third quarter valued at approximately $317,617,000. Baillie Gifford & Co. purchased a new position in United Therapeutics during the fourth quarter valued at approximately $157,390,000. Balyasny Asset Management L.P. lifted its holdings in United Therapeutics by 863.9% during the second quarter. Balyasny Asset Management L.P. now owns 152,727 shares of the biotechnology company’s stock valued at $43,886,000 after purchasing an additional 136,883 shares in the last quarter. Sofinnova Investments Inc. purchased a new position in United Therapeutics during the second quarter valued at approximately $34,055,000. Finally, Orbimed Advisors LLC purchased a new position in United Therapeutics during the third quarter valued at approximately $48,167,000. Institutional investors own 94.08% of the company’s stock.

Key Stories Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Neutral Sentiment: CEO Martine Rothblatt sold 9,500 shares for about $5.5 million, trimming her stake by 19%; CFO James Edgemond also sold 10,000 shares for about $5.7 million, reducing his ownership by 34.6%. These sizable insider transactions can make investors cautious about near-term sentiment. Article Title
• Neutral Sentiment: Director Nilda Mesa also sold 258 shares, a smaller transaction that adds to the recent insider selling trend. Article Title
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $660 price target, despite trimming its FY2030 earnings estimate slightly. Broader analyst coverage remains constructive, with a consensus rating of Moderate Buy and a target around $619.42, which may help support the stock. Article Title

Insider Activity at United Therapeutics

In other United Therapeutics news, CFO James Edgemond sold 10,000 shares of the business’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $574.47, for a total value of $5,744,700.00. Following the sale, the chief financial officer owned 18,876 shares in the company, valued at $10,843,695.72. The trade was a 34.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the stock in a transaction that occurred on Wednesday, May 13th. The shares were sold at an average price of $578.65, for a total value of $5,497,175.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at approximately $23,442,847.45. The trade was a 19.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 521,413 shares of company stock worth $289,410,912 in the last quarter. 8.60% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several brokerages have weighed in on UTHR. Cantor Fitzgerald lifted their price target on shares of United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. UBS Group upped their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a report on Thursday, March 5th. HC Wainwright upped their target price on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a report on Thursday, May 7th. Finally, TD Cowen increased their target price on United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a research report on Monday, March 30th. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

United Therapeutics Price Performance

United Therapeutics stock opened at $568.58 on Friday. The stock has a market cap of $24.14 billion, a P/E ratio of 20.99, a PEG ratio of 1.82 and a beta of 0.60. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35. The firm’s 50 day moving average price is $558.07 and its 200-day moving average price is $507.08.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The company’s quarterly revenue was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $6.63 EPS. As a group, equities analysts expect that United Therapeutics Corporation will post 27.64 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.